Many malls are struggling but IKEA is betting it can breathe new life into the troubled format.
Ingka Group, the operator of most of the world's IKEA stores, has assembled its own mall empire in recent years, spanning from China to Europe to the U.S., and says it wants to buy more locations as it aims to diversify beyond retail.
The company's blueprint is to anchor its malls with an IKEA store and seek to pull in more would-be shoppers with additions such as WeWorkstyle co-working spaces, Nordic-themed food halls and children's play areas inspired by outer space.
"People are looking for places that offer much more, not only shopping," said Cindy Andersen, the managing director of Ingka Centers, the company's real-estate arm. "If you bring in more reasons to visit, then people will still come."
Many malls have been in decline for years as consumers shift toward local, outdoor shopping venues and buy more online. Foot traffic to U.S. malls was down 4% on average in 2023 from the prior year, and about 12% lower than 2019 levels, according to Green Street, a real-estate data provider.
Some retailers, tracking their audience, have been reducing their exposure to enclosed malls, moving instead into strip malls or downtown locations.
Even so, the IKEA operator is doubling down on the mall. Though it offloaded its 14 malls in Russia last year following the country's invasion of Ukraine, Ingka still has 38 malls in 15 countries.
Ingka opened its first mall, or meeting place as it calls them, in 1973 in Sundsvall, Sweden, together with an IKEA store. In recent years the company has expanded its real-estate business, opening a string of new malls, and says it is actively looking to buy and develop more locations, including in the U.S.
The company looks for malls with strong existing retail tenants but with development potential, Andersen said.
This story is from the February 27, 2024 edition of Mint Mumbai.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the February 27, 2024 edition of Mint Mumbai.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Think Tesla Is In Trouble? Pity Even More Its Wannabe EV Rivals
The combined market value of six prominent wannabes hit 400bn in 2021, but today they are worth 65bn
Has The Growth Of Our Economy Translated Into Domestic Jobs?
While the covid shock and other setbacks got in the way, data indicates that employment in India is on a firm recovery path
How not to blow a major chunk of your travel budget on visas
Rejection of visas can impact your travel costs, especially when you have to cancel flight and hotel bookings
Ghosh won't stay on Bandhan Bank board
Board may even look at appointing an interim CEO post his tenure
Aakash names Deepak Mehrotra as managing director and CEO
Aakash Educational Services Ltd (AESL), a subA sidiary of embattled startup Byju's, has appointed Deepak Mehrotra as its managing director and chief executive officer.
Market cap of BSE-listed companies hits ₹400 trillion milestone
The Indian stock market's valuation crossed ₹400 trillion in a historic milestone on Monday, with the last ₹100 trillion rolling in the shortest duration of a mere 9 months, as the country's bright macroeconomic fundamentals encouraged local and foreign investors to plough more money into equities.
New Wipro CEO must cover a lot of ground
The sudden resignation of Thierry Delaporte as Wipro Ltd's chief executive officer is the last thing investors in the company want to deal with.
Synchron readies large-scale brain implant trial
Synchron Inc, a rival to Elon Musk's Neuralink brain implant startup, is preparing to recruit patients for a large-scale clinical trial required to seek commercial approval for its device, the company's chief executive told Reuters.
Alibaba slashes cloud prices globally as AI demand quickens
Alibaba Group Holding Ltd. is cutting prices for cloud customers from the US to Singapore by as much as 59%, mirroring deep discounts at home as the once high-flying division struggles to fend off rivals and revive growth.
Piramal Alternatives invests ₹110 cr in Biodeal Pharma
As contract manufacturing becomes the new A growth driver of the pharmaceutical industry, Piramal Alternatives, the fund management business of the Piramal Group, on Monday announced an investment of ₹110 crore in Biodeal Pharmaceuticals Ltd, a contract development and manufacturing organization.